Azeez  Farooki MD's portrait

Azeez Farooki MD

Assistant Attending Physician, Endocrinology Service
Memorial Sloan-Kettering Cancer Center
New York, NY

About Azeez Farooki MD

Dr. Azeez Farooki is an academic endocrinologist practicing in New York City. His expertise includes general endocrinology with a sub-focus in osteoporosis / metabolic bone diseases.

He has published in the New England Journal of Medicine, Journal of Clinical Oncology, and Journal of Clinical Endocrinology and Metabolism. Twice, Dr. Farooki served on the National Comprehensive Cancer Network (NCCN) taskforce for Bone Health in Cancer Care. Furthermore, he has served on the PI3 kinase, Akt inhibitor, MTOR inhibitor Task Force to the Investigational Drug Steering Committee of the National Cancer Institute of the National Institutes of Health (NIH).

Publications

Peer Reviewed Articles

1. Farooki A. Impact 1.5 tube feedings and morbidity (January-February 2005) [Letter]. JPEN J Parenter Enteral Nutr. Nov-Dec;29(6):455.

2. Farooki A. Clinical Pearl: Vitamin D deficiency and osteoporosis [Commentary]. Cortlandt Forum. Apr 2005.

3. Farooki A, Amorosa LF. Idiopathic hypercalciuria as an etiology for persistent post-operative hypercalcemia [Letter]. Surgery. 2005 Nov;138(5):961-2.

4. Farooki A, Wang X. Transient subclinical hyperparathyroidism in a patient with hashimoto's thyroiditis. Endocr Pract. 2006 May-Jun;12(3):338-40.

5. Farooki A, Schneider SH. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin [Letter]. Diabetes Care. 2006 Aug;29(8):1989-90.

6. Farooki A, Schneider SH. Insulin resistance and cancer-related mortality [Letter]. J Clin Oncol. 2007 Apr 20;25(12):1628-9.

7. Farooki A, Fornier M, Girotra M. Anabolic therapies for osteoporosis [Letter]. N Engl J Med. 2007 Dec 6;357(23):2410-1.

8. Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM. Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy. Oncologist. 2008;13(8):911-920. Epub 2008 Aug 11.

9. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008 Aug 20;26(24):4037-8.

10. Gralow J, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw. 2009 Jun;7 Suppl 3:S1-S32; quiz S33-S35.

11. Farooki A. Central obesity and increased risk of dementia more than three decades later [Letter]. Neurology. 2009 Mar 17;72(11):1030-1.

12. Cremers SC, Farooki A. Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. Ann N Y Acad Sci. 2010 Sep 29.

13. Puhaindran ME, Farooki A, Steensma MR, Hameed M, Healey JH, Boland PJ. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. Bone Joint Surg Am. 2011 Jul 6;93(13):1235-42.

14. Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, Patil S, Fleisher M, Cremers S, Huryn J, Hudis CA, Fornier MN. Serum N-Telopeptide and Bone-Specific Alkaline Phosphatase Levels in Patients With Osteonecrosis of the Jaw Receiving Bisphosphonates for Bone Metastases. J Oral Maxillofac Surg. 2012 Feb 11.

15. Wei X, Pushalkar S, Estilo C, Wong C, Farooki A, Fornier M, Bohle G, Huryn J, Li Y, Doty S, Saxena D. Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw. Oral Dis. 2012 Feb 22.

16. Farooki A, Busaidy NL, Sui L, et al. Management of Metabolic Effects (Hyperlipidemia and Hyperglycemia) Associated with Anticancer Agents Targeting the PI3K-Akt-mTOR (PAM) Pathway. J Clin Oncol. 2012 Aug 10;30(23):2919-28.

17. Skeletal-Related Events due to Bone Metastases from Differentiated Thyroid Cancer. Farooki A, Leung V, Tala H, Tuttle RM. J Clin Endocrinol Metab. 2012 Jul;97(7):2433-9. Epub 2012 May 7.

18. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Berman E, Girotra M, Cheng C, Chanel S, Maki R, Shelat M, Strauss HW, Fleisher M, Heller G, Farooki A. Leuk Res. 2013 Mar 5.

Books, Book Chapters, and Reviews

Farooki A, Chua H. 2009. Osteoporosis. In: Stubblefield M, O'Dell MW, editors. Principles & Practice of Cancer Rehabilitation, 1st ed. New York: Demos Medical Publishing. p. 753-771.

Farooki A. 2012. Hypercalcemia. In: Laufgraben M, Gopalakrishnan G, editors. Tarascon Adult Endocrinology Pocketbook.

Articles Written by Azeez Farooki MD

Hypothyroidism: What You Should Know About Your Treatment
Doctors typically prescribe a medication called levothyroxine, a synthetic form of thyroid hormone replacement. However, some people with hypothyroidism have difficulty tolerating or absorbing the traditional medication.

Financial Disclosures for Azeez Farooki MD

EndocrineWeb, a Vertical Health, LLC website, is committed to ensuring that the medical information it presents is accurate, balanced, objective, and trustworthy.

To help achieve this goal, EndocrineWeb requires all authors, editors, and reviewers to disclose any financial relationships or affiliations they have with companies whose products or services may be mentioned in the content they author, edit, or review.

The intent of this policy is to identify any perceived, potential, or real conflicts of interest so that readers can make their own judgments about the value of information being presented.

Author's Statement

I, or an immediate family member, have a financial interest(s) or affiliation(s) with the following commercial companies whose products and / or services may be mentioned in the materials I have authored, edited or reviewed for presentation on Vertical Health, LLC’s websites.

Disclosed Relationships

Consultant
AKRIMAX Pharmaceuticals
SHOW MAIN MENU
SHOW SUB MENU